about
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival.Rescue therapy using an endobronchial valve and digital air leak monitoring in Invasive Pulmonary Aspergillosis.Quantitative estimation of right ventricular hypertrophy using ECG criteria in patients with pulmonary hypertension: A comparison with cardiac MRI.Vascular function assessed with cardiovascular magnetic resonance predicts survival in patients with advanced chronic kidney disease.Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational studyDose De-escalation of Intrapleural Tissue Plasminogen Activator Therapy for Pleural Infection. The Alteplase Dose Assessment for Pleural Infection Therapy Project.Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest GroupThe diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.Empyema necessitans and a persistent air leak associated with rupture of an anaerobic lung abscess due to bacteroides.Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'.Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery.Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study.Estimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening.Assessment of the presence of occult myocardial infarction in chronic obstructive pulmonary disease using contrast-enhanced cardiac magnetic resonance imaging.Progress and challenges in Mesothelioma: From bench to bedside.Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors.Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies.Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy.Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging.Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension.Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion.Measurement of Pulse Wave Velocity using Magnetic Resonance ImagingProviding safe and effective pleural medicine services in the UK: an aspirational statement from UK pleural physiciansPulmonary arterial pulse pressure and mortality in pulmonary arterial hypertensionInter-observer variation in image interpretation and the prognostic importance of non-expansile lung in malignant pleural effusion
P50
Q30240296-992CA4AE-B77F-4B12-A61C-89DBD02FF9AAQ33788527-D1E74351-B226-4766-84F9-247A82AFFB81Q35166705-ABEC0A90-BFC1-41EA-94F9-BC4D41F82CA5Q35896201-46588B91-E0AE-43B6-8E23-3358EC4DD8BAQ36862427-EF120DC6-159F-487D-9B66-1E7543979AF0Q37516709-DEBA955D-6733-4CBB-8995-2E69FF70A8F8Q38742124-9380A240-A7EF-49AC-8D22-C1F5AFFBD134Q38994262-D77B600A-C09E-40AD-9B48-C143A4EE51F4Q39063801-C69EDB8A-859C-46FA-93B5-B6F11B4CDC9CQ40077290-9C86E6B7-66D0-472D-B143-769B7D9B6F8BQ40169633-0C1F45EC-7C50-4F88-AF0F-062944AD8B2FQ41710839-97172FA1-75CA-4EF6-BBE8-1BDBCF869E06Q45386848-47771658-D8AF-4C23-81C7-1CDCA43BD07EQ47744682-FDD9DF31-6DD5-4013-BBC8-B8F5EE2FEA11Q48739496-661C1DCC-BEA7-4EFA-B5BF-029774C90793Q50056410-B7B42428-45EB-414D-967B-9C78E7144EEAQ50286398-CAF03FAC-A6D1-44F7-B2F1-59644B94BC27Q51676810-598CEB3E-1CBB-4805-9EC1-424B9409EDF4Q51731968-D932625C-BB3D-443D-9871-D71E8DE64EAAQ53549528-40D19853-25F5-483B-8BFC-8E0137BFD200Q53856653-6912624F-9A16-4520-AABE-F35F0625C60BQ55152523-9F7866D2-5785-462F-BA7A-1D167EFBB212Q57750278-C0BE6BF2-CB28-4409-82EE-B57014377067Q58801429-84008150-B6C8-4738-A9D7-B2F6F6C079FEQ80844429-DA18D752-31F1-4540-8E75-A105D66C9F1CQ92748315-E7A4FCF0-2162-427F-B9F0-CF6B9DA48DDE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kevin G Blyth
@ast
Kevin G Blyth
@en
Kevin G Blyth
@es
Kevin G Blyth
@nl
type
label
Kevin G Blyth
@ast
Kevin G Blyth
@en
Kevin G Blyth
@es
Kevin G Blyth
@nl
prefLabel
Kevin G Blyth
@ast
Kevin G Blyth
@en
Kevin G Blyth
@es
Kevin G Blyth
@nl
P106
P1153
8921989700
P21
P31
P496
0000-0003-2972-6641